Tel Aviv Sourasky Medical Center Chooses SOPHiA DDMTM HRD Solution of SOPHiA GENETICS
April 04 2023 - 9:00AM
Business Wire
SOPHiA DDMTM HRD Solution will help empower
clinical researchers to advance cancer research
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company
in the healthcare space and a leader in data-driven medicine, today
announced that Tel Aviv Sourasky Medical Center (Ichilov), the
largest acute care facility in Israel, has chosen to use SOPHiA
DDM™ to enhance its genetic testing capabilities. The facility,
which serves a population of one million people, will use the
SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution to
help advance its clinical oncology research.
HRD is caused by a cell’s impaired ability to repair DNA
double-stranded breaks through the homologous recombination repair
(HRR) pathway and is a common feature of high-grade serous ovarian
cancer (HGSOC) as well as breast, prostate, and pancreatic cancers.
For those diagnosed with these cancer types, HRD can be used as a
potential predictive biomarker for therapy response.
The SOPHiA DDMTM HRD Solution provides a unique approach to
molecular cancer testing by combining the identification of
HRD-causing mutations with the analysis of HRD-induced genomic
instability across the whole genome of tumor samples. By
implementing SOPHiA DDMTM HRD Solution, Tel Aviv Sourasky Medical
Center (Ichilov) will have the opportunity to identify larger
populations of individuals with HRD-positive cancer who may benefit
from treatment with PARP inhibitors (PARPi).
“The implementation of methods able to detect HRD is crucial for
identifying patients who could benefit from treatment with PARPi,”
said Dr. Ariel Erental, Tel Aviv Sourasky Medical Center. “The
SOPHiA DDMTM HRD Solution will help to inform data-driven decisions
that advance the clinical research at Tel Aviv Sourasky Medical
Center into HRD-associated cancers.”
SOPHiA DDMTM HRD Solution enables laboratories and healthcare
institutions to identify HRR mutations and measure genomic
instability via a decentralized approach. This approach to HRD
testing for tumor samples allows the users to retain full ownership
of their data, saving time and expense, while offering
comprehensive genomic insights powered by deep learning
algorithms.
“SOPHiA GENETICS is working to make data-driven medicine more
broadly accessible to patients around the globe,” said Ken
Freedman, Chief Revenue Officer, SOPHiA GENETICS. “By implementing
SOPHiA DDMTM HRD Solution, Tel Aviv Sourasky Medical Center will
have access to high analytical performance and streamlined
bioinformatics workflows, making it more efficient to detect HRD
status in advanced ovarian cancer and other relevant cancers.”
In addition to supporting Tel Aviv Sourasky Medical Center in
its work to detect HRD status in select cancers, the powerful
analytics of SOPHiA DDMTM HRD Solution will help the Medical Center
maximize in-house genomic insights to help advance its clinical
research capabilities.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn,
Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing the practice of data-driven medicine as the
standard of care and for life sciences research. It is the creator
of the SOPHiA DDM™ Platform, a cloud-native platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
a broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook, and Instagram.
Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management’s beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230404005766/en/
Media: Nick Puleo npuleo@comsint.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024